ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Barcelona, CT, ESP:

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

Barcelona, Spain and 15 other locations

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have e...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: HMPL-523

Phase 1

HUTCHMED
HUTCHMED

Barcelona, Spain and 31 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Barcelona, Spain and 89 other locations

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Barcelona, Catalunya, Spain and 66 other locations

1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for whic...

Enrolling
Lymphoma
Solid Tumor, Adult
Drug: Fadraciclib

Phase 1, Phase 2

Cyclacel Pharmaceuticals

Barcelona, Spain and 3 other locations

pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma...

Enrolling
B-cell Non-Hodgkin Lymphoma
B-cell Lymphoma
Drug: IKS03

Phase 1

Iksuda Therapeutics

Badalona, Spain and 12 other locations

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....

Enrolling
Lymphoma, T-Cell
Diffuse Large B Cell Lymphoma
Drug: CPI-0209

Phase 1, Phase 2

Constellation Pharmaceuticals

Barcelona, Spain and 59 other locations

on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back af...

Enrolling
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Barcelona, Spain and 131 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: vinblastine
Drug: brentuximab vedotin

Phase 3

Takeda
Takeda

Barcelona, Spain and 215 other locations

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during...

Enrolling
Marginal Zone Lymphoma
Follicular Lymphoma
Biological: rituximab
Biological: EO2463

Phase 1, Phase 2

Enterome

Barcelona, Spain and 11 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems